Super Oversight for Generics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Super Oversight for Generics



The Office of Generic Drugs (OGD) is now officially a “super” office in FDA’s Center for Drug Evaluation and Research (CDER), with more divisions and staffers added to better manage application reviews, product safety and regulatory oversight. OGD will review bioequivalence and clinical studies and product labeling, with added support from new offices for policy and regulatory science. OGD acting director Kathleen Uhl continues to head the operation, including a transition team to manage staff shifts. However, some 200 chemists and microbiologists will remain in CDER’s Office of Pharmaceutical Science pending establishment of a new Office of Pharmaceutical Quality in CDER that will house CMC and microbiology review functions for both new drugs and generics.

“Super” OGD is under pressure to improve review operations, as generic-drug manufacturers have become increasingly vocal about FDA’s slow pace in approving new abbreviated new drug applications (ANDAs) and reducing the application backlog. Newly instituted generic-drug user fees went up for 2014, which was expected under the Generic Drug User Fee Act, but now small firms are seeking exemptions to facility fees they consider burdensome. Fees on production plants run more than $200,000 a year and have to be paid while an ANDA awaits approval, which still can take years. Companies without other products on the market claim that this is a hardship, and legislation has been proposed to set up a fee waiver request process. The bill is unlikely to pass, but puts more pressure on FDA to improve the generic-drug review program.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here